- - - - - - -
You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Although scientific consensus of the appropriate diagnostic criteria continues to evolve, 3 recognized options for confirming a diagnosis of primary HLH exist1-4:
In 1994, as part of the HLH-94 clinical trial, the Histiocyte Society proposed a standard definition of HLH. Click to expand this version.
When it comes to treating primary HLH, there is no time to wait. Prior to receiving the results of a genetic test, ancillary testing and flow cytometry can be used, where available, to help differentiate between primary and secondary HLH. This approach helps find the triggers or underlying causes of HLH and prevents misdiagnosis.3,5,7,8
Consider running the following tests3:
Consider checking for decreased levels of3,7:
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.1-4
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.7
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.7
Contact your Sobi Health Systems Director to understand Gamifant ordering options. Connect with your Reimbursement Manager for your individual patient's insurance coverage policy and reimbursement pathway.